Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy of Neurology Annual Meeting
Analysis Suggests Use of RADICAVA IV is Associated with Improved
tanabe
Mitsubishi Tanabe Pharma America to Showcase ALS Research at 2022 American Academy of Neurology Annual Meeting
Presentations Include Real-World Data on RADICAVA® (edaravone) and Results from
Mitsubishi Tanabe Pharma America Highlights ALS Research at 2022 MDA Clinical & Scientific Conference
JERSEY CITY, N.J., March 11, 2022 — Mitsubishi Tanabe Pharma